Seeking Alpha

Depomed soars after royalty, milestone deal with PDL

  • Investors appear to be cheering Depomed's (DEPO) move to sell diabetes royalty and milestone rights to PDL BioPharma (PDLI).
  • DEPO +13% premarket
  • More on the deal here
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: